home | healthcare and medical | company profile

Biovail Corporation - Corporate and Strategic Assessment Report - Company Strategy, SWOT Analysis (Datamonitor)

Market: Healthcare and Medical
Published Date: 06 Nov 2008
Table of Contents: Biovail Corporation - Corporate and Strategic Assessment Report - Company Strategy, SWOT Analysis
Report Type: Company Profile
Country: Global
Number of Pages: 56

Subscription Accounts

Companiesandmarkets.com holds over 500,000 market research reports and company profiles. Companies rely upon us to obtain a complete view of research available and purchase Subscription Accounts to our content. Contact Us to find out more.

Introduction

Biovail is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products, utilizing advanced drug-delivery technologies. The company currently has over 20 distinct, proprietary drug-delivery technologies, and has access to other technologies through licensing agreements with development partners.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis

Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors

Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Biovail's branded products in Canada include: Tiazac XC, Wellbutrin XL, Glumetza, Lescol, Lescol XL and Zyban. The company's wholly-owned US subsidiary includes administrative, product distribution and related regulatory affairs functions. Its products include Cardizem CD, Ativan, Vaseretic, Vasotec, and Isordil.

Biovail derives its revenues primarily from the sales of pharmaceutical products developed and manufactured by the company, as well as sales of proprietary and in-license products;pharmaceutical clinical research and laboratory testing services, and product development activities in collaboration with third parties;

The company's total revenues increased at a CAGR of 7.9% during 2002-2006, from $788 million to $1,067.7 million. This represents an absolute total growth of +$279.7 million for total revenues. The increase is primarily attributable to increased product sales.

Reasons to Purchase

Access all the important information and analysis on the company in a single report

Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain

Gain access to company's adjusted five year financial data along with key ratios and market capitalization

£265.00		Share Report
Select Pricing [?]		Enquire About Report
Report Delivery	Report Delivery: Via Email	Send to a Colleague
Change Currency	Euro USD GBP

Companiesandmarkets.com provides a wide range of industry statistics, market research reports and industry reports providing market size, trends, analysis, competitive intelligence, company profiles, SWOT analysis reports, company analysis and forecasts.

Purchase Information

There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card, Credit Card, or by Invoice.

Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.

Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.

Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.